Botanix Pharmaceuticals

Advancing new treatments for skin disease and infections

Pharmaceutical company leveraging the unique properties of synthetic cannabinoids with its Permetrex™ technology

Promising R&D, with a rapidly advancing pipeline of dermatology and antimicrobial products

World-class team with extensive cannabinoid drug development and commercialisation expertise

Evidence, first

Botanix Pharmaceuticals is a clinical stage dermatology company developing novel treatments for common skin diseases and infection leveraging its novel delivery technology, Permetrex™.

We have attracted a world-class team and significant capital to support the progression of our products. We are moving quickly, but never at the expense of our rigorous commitment to ethical research and development (R&D) and the highest clinical standards mandated by the US Food and Drug Administration (FDA). Our goal is to unlock the true potential of synthetic cannabinoids for people around the world, with an evidence-first approach.

Check out our latest news

AGM Presentation

Botanix Pharmaceuticals (ASX:BOT) is today hosting its Annual…

Vince Ippolito speaks with Proactive

Botanix President and Executive Chairman, Vince Ippolito, was…

Dermatology Update

Botanix Pharmaceuticals (ASX:BOT) has today provided an update…

Botanix Expands Management Team

Botanix (ASX:BOT) has expanded its management team with the…

4th International Cannabinoid Derived Pharmaceuticals Summit

Botanix is delighted to be attending the 4th International Cannabinoid…

Corporate Update Presentation

Botanix Pharmaceuticals has released a corporate presentation…

Botanix FY21 Annual Report

Botanix (ASX:BOT) has today published its its Annual Report…

Research Report by Euroz Hartleys

Botanix (ASX:BOT) is pleased to advise that leading adviser…

Invest in innovation

Botanix Pharmaceuticals offers a compelling opportunity for investors who are interested in capitalising on the clinical potential of synthetic cannabinoids. Our clinical trials to date have highlighted the unique mechanism of action which drives synthetic cannabidiol to produce anti-inflammatory and antimicrobial effects. We are leveraging this evidence to inform the development of new pharmaceutical products, targeting some of the most underserved and lucrative segments of the global healthcare market. Already, we have one of the most advanced clinical pipelines for synthetic cannabinoids in the world.

New treatments, in demand

Botanix has generated strong scientific support for the anti-inflammatory and antimicrobial mechanisms of action of synthetic cannabinoids with application in the development of novel dermatology and bacteria fighting applications.

There have been no new chemical entities (NCE’s) in topical drugs approved for acne in more than two decades and resistance to available antibiotics remains a significant global issue, with no new classes of antibiotics approved in more than three decades. When bacteria survive exposure to antibiotics that would normally eliminate them, these surviving bacteria grow and spread resistance, leading to the emergence of ‘superbugs’. New treatments in dermatology and anti-microbials are needed now.

Botanix periodically runs clinical studies in Australia, New Zealand the USA. Share your details if you would like to learn more.

Sign up to receive our latest news.

Processing...
Thank you! Your subscription has been confirmed. You'll hear from us soon.
ErrorHere